中文English
ISSN 1001-5256
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

肌肉生长抑制素与终末期肝病肌肉减少症的关系

赵琴 杨军杰 钟炎平 李姗 刘园园 雷旭 刘龙 谭华炳

赵琴,杨军杰,钟炎平,等. 肌肉生长抑制素与终末期肝病肌肉减少症的关系[J]. 临床肝胆病杂志, 2021, 37(11): 2692-2695. DOI: 10.3969/j.issn.1001-5256.2021.11.045.
引用本文: 赵琴,杨军杰,钟炎平,等. 肌肉生长抑制素与终末期肝病肌肉减少症的关系[J]. 临床肝胆病杂志, 2021, 37(11): 2692-2695. DOI: 10.3969/j.issn.1001-5256.2021.11.045.
ZHAO Q, YANG JJ, ZHONG YP, et al. Association between myostatin and sarcopenia in end-stage liver disease[J]. J Clin Hepatol, 2021, 37(11): 2692-2695. DOI: 10.3969/j.issn.1001-5256.2021.11.045.
Citation: ZHAO Q, YANG JJ, ZHONG YP, et al. Association between myostatin and sarcopenia in end-stage liver disease[J]. J Clin Hepatol, 2021, 37(11): 2692-2695. DOI: 10.3969/j.issn.1001-5256.2021.11.045.

肌肉生长抑制素与终末期肝病肌肉减少症的关系

DOI: 10.3969/j.issn.1001-5256.2021.11.045
基金项目: 

2021年十堰市科学技术研究与开发项目计划 2021K65;

湖北省卫生健康委员会2019-2020年度科研项目 WJ2019F051;

2018年湖北省教育厅基金项目 B2018117

详细信息
    通信作者:

    谭华炳,renmthb@163.com

  • 中图分类号: R575

Association between myostatin and sarcopenia in end-stage liver disease

Research funding: 

2021 Shiyan Research and Development Program of Science and Technology 2021K65;

2019-2020 Hubei Provincial Health Commission Foundation WJ2019F051;

2018 Hubei Provincial Education Department Foundation B2018117

  • 摘要: 终末期肝病(ESLD)患者普遍存在肌肉减少症(MD)和脂肪减少为代表的恶病质状态,既往认为这种状态与营养不良相关。近年来发现肌肉生长抑制素(MSTN)与ESLD病情进展相关。研究发现MSTN通过影响糖、脂肪、蛋白质代谢及肌细胞数量等导致MD、恶病质状态;MSTN可以作为HCC的筛查指标、病情进展观察指标。通过MSTN途径干预可能是控制ESLD患者MD、恶病质的有效方法,是预测肝硬化向HCC发展的有效指标。

     

  • [1] CRUZ-JENTOFT AJ, BAEYENS JP, BAUER JM, et al. Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on sarcopenia in older people[J]. Age Ageing, 2010, 39(4): 412-423. DOI: 10.1093/ageing/afq034.
    [2] GU DH, KIM MY, SEO YS, et al. Clinical usefulness of psoas muscle thickness for the diagnosis of sarcopenia in patients with liver cirrhosis[J]. Clin Mol Hepatol, 2018, 24(3): 319-330. DOI: 10.3350/cmh.2017.0077.
    [3] SHI ZW, LI J, ZENG X, et al. Application of L3 skeletal muscle index in evaluating prognosis of diseases[J]. Acad J Sec Mil Med Univ, 2019, 40(4): 420-425. DOI: 10.16781/j.0258-879x.2019.04.0420.

    石志文, 李娟, 曾欣, 等. L-3骨骼肌指数在疾病预后评估中的应用[J]. 第二军医大学学报, 2019, 40(4): 420-425. DOI: 10.16781/j.0258-879x.2019.04.0420.
    [4] HOSOYAMA T, YAMANOUCHI K, NISHIHARA M. Role of serum myostatin during the lactation period[J]. J Reprod Dev, 2006, 52(4): 469-478. DOI: 10.1262/jrd.18009.
    [5] HILL JJ, QIU Y, HEWICK RM, et al. Regulation of myostatin in vivo by growth and differentiation factor-associated serum protein-1: A novel protein with protease inhibitor and follistatin domains[J]. Mol Endocrinol, 2003, 17(6): 1144-1154. DOI: 10.1210/me.2002-0366.
    [6] MCPHERRON AC, LAWLER AM, LEE SJ. Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member[J]. Nature, 1997, 387(6628): 83-90. DOI: 10.1038/387083a0.
    [7] GAO F, KISHIDA T, EJIMA A, et al. Myostatin acts as an autocrine/paracrine negative regulator in myoblast differentiation from human induced pluripotent stem cells[J]. Biochem Biophys Res Commun, 2013, 431(2): 309-314. DOI: 10.1016/j.bbrc.2012.12.105.
    [8] BOGDANOVICH S, MCNALLY EM, KHURANA TS. Myostatin blockade improves function but not histopathology in a murine model of limb-girdle muscular dystrophy 2C[J]. Muscle Nerve, 2008, 37(3): 308-316. DOI: 10.1002/mus.20920.
    [9] MCPHERRON AC, LEE SJ. Suppression of body fat accumulation in myostatin-deficient mice[J]. J Clin Invest, 2002, 109(5): 595-601. DOI: 10.1172/JCI13562.
    [10] CHOI SJ, YABLONKA-REUVENI Z, KAIYALA KJ, et al. Increased energy expenditure and leptin sensitivity account for low fat mass in myostatin-deficient mice[J]. Am J Physiol Endocrinol Metab, 2011, 300(6): E1031-E1037. DOI: 10.1152/ajpendo.00656.2010.
    [11] GUO T, JOU W, CHANTURIYA T, et al. Myostatin inhibition in muscle, but not adipose tissue, decreases fat mass and improves insulin sensitivity[J]. PLoS One, 2009, 4(3): e4937. DOI: 10.1371/journal.pone.0004937.
    [12] PELUSO G, NICOLAI R, REDA E, et al. Cancer and anticancer therapy-induced modifications on metabolism mediated by carnitine system[J]. J Cell Physiol, 2000, 182(3): 339-350. DOI: 10.1002/(SICI)1097-4652(200003)182:3<339::AID-JCP4>3.0.CO;2-B.
    [13] MASTROGIOVANNI M, TROSTCHANSKY A, RUBBO H. Fatty acid nitration in human low-density lipoprotein[J]. Arch Biochem Biophys, 2020, 679: 108190. DOI: 10.1016/j.abb.2019.108190.
    [14] SCHUMACKER PT. Reactive oxygen species in cancer cells: Live by the sword, die by the sword[J]. Cancer Cell, 2006, 10(3): 175-176. DOI: 10.1016/j.ccr.2006.08.015.
    [15] SUZUKI K. Chronic inflammation as an immunological abnormality and effectiveness of exercise[J]. Biomolecules, 2019, 9(6): 223. DOI: 10.3390/biom9060223.
    [16] BRAND KA, HERMFISSE U. Aerobic glycolysis by proliferating cells: A protective strategy against reactive oxygen species[J]. FASEB J, 1997, 11(5): 388-395. DOI: 10.1096/fasebj.11.5.9141507.
    [17] WAGNER KR, FLECKENSTEIN JL, AMATO AA, et al. A phase Ⅰ/Ⅱtrial of MYO-029 in adult subjects with muscular dystrophy[J]. Ann Neurol, 2008, 63(5): 561-571. DOI: 10.1002/ana.21338.
    [18] VAUPEL P, MULTHOFF G. Revisiting the Warburg effect: Historical dogma versus current understanding[J]. J Physiol, 2021, 599(6): 1745-1757. DOI: 10.1113/JP278810.
    [19] BURGESS K, XU T, BROWN R, et al. Effect of myostatin depletion on weight gain, hyperglycemia, and hepatic steatosis during five months of high-fat feeding in mice[J]. PLoS One, 2011, 6(2): e17090. DOI: 10.1371/journal.pone.0017090.
    [20] TANDON P, NEY M, IRWIN I, et al. Severe muscle depletion in patients on the liver transplant wait list: Its prevalence and independent prognostic value[J]. Liver Transpl, 2012, 18(10): 1209-1216. DOI: 10.1002/lt.23495.
    [21] ZHAO LL, LIU XG, CHEN PJ, et al. The regulatory effect of myostatin on skeletal muscle and its clinical value[J]. Chin J Rehabil Med, 2018, 33(5): 616-621. DOI: 10.3969/j.issn.1001-1242.2018.05.025.

    赵淋淋, 刘晓光, 陈佩杰, 等. 肌肉生长抑制素对骨骼肌的调控作用及其临床价值[J]. 中国康复医学杂志, 2018, 33(5): 616-621. DOI: 10.3969/j.issn.1001-1242.2018.05.025.
    [22] HAN HQ, ZHOU X, MITCH WE, et al. Myostatin/activin pathway antagonism: Molecular basis and therapeutic potential[J]. Int J Biochem Cell Biol, 2013, 45(10): 2333-2347. DOI: 10.1016/j.biocel.2013.05.019.
    [23] MERLI M, GIUSTO M, LUCIDI C, et al. Muscle depletion increases the risk of overt and minimal hepatic encephalopathy: Results of a prospective study[J]. Metab Brain Dis, 2013, 28(2): 281-284. DOI: 10.1007/s11011-012-9365-z.
    [24] ONISHI S, SHIRAKI M, NISHIMURA K, et al. Prevalence of sarcopenia and its relationship with nutritional state and quality of life in patients with digestive diseases[J]. J Nutr Sci Vitaminol (Tokyo), 2018, 64(6): 445-453. DOI: 10.3177/jnsv.64.445.
    [25] van VUGT JL, LEVOLGER S, de BRUIN RW, et al. Systematic review and meta-analysis of the impact of computed tomography-assessed skeletal muscle mass on outcome in patients awaiting or undergoing liver transplantation[J]. Am J Transplant, 2016, 16(8): 2277-2292. DOI: 10.1111/ajt.13732.
    [26] HU L, HU R, WANG N, et al. Research progress of Mstn gene[J]. Chin J Veterin Med, 2004, 38(1): 41-43. DOI: 10.3969/j.issn.1002-1280.2004.01.014.

    胡兰, 胡锐, 王娜, 等. Mstn基因的研究进展[J]. 中国兽药杂志, 2004, 38(1): 41-43. DOI: 10.3969/j.issn.1002-1280.2004.01.014.
    [27] KOBAYASHI A, KAIDO T, HAMAGUCHI Y, et al. Impact of sarcopenic obesity on outcomes in patients undergoing hepatectomy for hepatocellular carcinoma[J]. Ann Surg, 2019, 269(5): 924-931. DOI: 10.1097/SLA.0000000000002555.
    [28] HAMID T, MALIK MT, KAKAR SS. Ectopic expression of PTTG1/securin promotes tumorigenesis in human embryonic kidney cells[J]. Mol Cancer, 2005, 4(1): 3. DOI: 10.1186/1476-4598-4-3.
    [29] OKAMOTO H, TANIGUCHI A, USAMI S, et al. Inactivation of myostatin by photo-oxygenation using catalyst-functionalized peptides[J]. Chem Commun (Camb), 2019, 55(62): 9108-9111. DOI: 10.1039/c9cc04368c.
    [30] LI YJ, LEI X, YIN H, et al. Pay attention to cirrhotic cardiomyopathy[J]. World Chin J Dig, 2016, 24(27): 3846-3852. DOI: 10.11569/wcjd.v24.i27.3846.

    李云静, 雷旭, 殷华, 等. 关注肝硬化性心肌病[J]. 世界华人消化杂志, 2016, 24(27): 3846-3852. DOI: 10.11569/wcjd.v24.i27.3846.
    [31] LEI X, LIU YY, XIE XR, et al. Effects of BuyangHuanwu decoction on endogenous H2S in myocardial tissue of cirrhotic cardiomyopathy rats[J]. Lishizhen Med Materia Med Res, 2018, 29(6): 1341-1343. DOI: SZGY.0.2018-06-021.

    雷旭, 刘园园, 谢杏榕, 等. 补阳还五汤对肝硬化性心肌病大鼠心肌组织内源性H2S的影响[J]. 时珍国医国药杂志, 2018, 29(6): 1341-1343. DOI: SZGY.0.2018-06-021.
    [32] KIM JH, KANG SH, LEE M, et al. Serum myostatin predicts the risk of hepatocellular carcinoma in patients with alcoholic cirrhosis: A multicenter study[J]. Cancers (Basel), 2020, 12(11). DOI: 10.3390/cancers12113347.
    [33] SUN MH, LIU L, YANG RP, et al. The diagnostic value of abnormal prothrombin combined with alpha-fetoprotein detection in HBV-related hepatocellular carcinoma[J/CD]. Chin J Hepatol (Electronic Edition), 2018, 10(4): 1- 6. DOI: GZBZ.0.2018-04-001.

    孙明辉, 刘龙, 杨瑞萍, 等. 异常凝血酶原联合甲胎蛋白检测在HBV相关肝细胞癌中的诊断价值[J/CD]. 中国肝脏病杂志(电子版), 2018, 10(4): 1-6. DOI: GZBZ.0.2018-04-001.
    [34] ZHAO Q, LIU YY, LEI X, et al. Application of abnormal prothrombin in screening HCC among patients with hepatitis B virus infection[J]. World Chin J Dig, 2017, 25(9): 803-809. DOI: 10.11569/wcjd.v25.i9.803.

    赵琴, 刘园园, 雷旭, 等. 应用异常凝血酶原在乙型肝炎病毒感染者中筛查HCC研究进展[J]. 世界华人消化杂志, 2017, 25(9): 803-809. DOI: 10.11569/wcjd.v25.i9.803.
    [35] NISHIKAWA H, ENOMOTO H, ISHⅡ A, et al. Elevated serum myostatin level is associated with worse survival in patients with liver cirrhosis[J]. J Cachexia Sarcopenia Muscle, 2017, 8(6): 915-925. DOI: 10.1002/jcsm.12212.
    [36] ZHAO C, WANG X, ZHAO Y, et al. A novel xenograft model in zebrafish for high-resolution investigating dynamics of neovascularization in tumors[J]. PLoS One, 2011, 6(7): e21768. DOI: 10.1371/journal.pone.0021768.
    [37] BONETTO A, PENNA F, AVERSA Z, et al. Early changes of muscle insulin-like growth factor-1 and myostatin gene expression in gastric cancer patients[J]. Muscle Nerve, 2013, 48(3): 387-392. DOI: 10.1002/mus.23798.
    [38] ZHOU X, WANG JL, LU J, et al. Reversal of cancer cachexia and muscle wasting by ActRⅡB antagonism leads to prolonged survival[J]. Cell, 2010, 142(4): 531-543. DOI: 10.1016/j.cell.2010.07.011.
  • 加载中
计量
  • 文章访问数:  106
  • HTML全文浏览量:  61
  • PDF下载量:  18
  • 被引次数: 0
出版历程
  • 收稿日期:  2021-04-19
  • 录用日期:  2021-05-10
  • 出版日期:  2021-11-20
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回